Operating as a clinical-stage biopharmaceutical firm, 9 Meters Biopharma, Inc. specialized in creating therapies for individuals in North America afflicted by rare digestive illnesses, various gastrointestinal disorders lacking effective treatments, and other debilitating conditions. Its primary therapeutic candidate was Vurolenatide, a long-acting injectable glucagon-like peptide-1, which had advanced to Phase 3 clinical trials for the management of short bowel syndrome. The company's pipeline also included NM-136, a humanized monoclonal antibody aimed at treating obesity and associated conditions; NM-102, a small molecule peptide designed to hinder antigen entry into the systemic circulation; and NM-003, a proprietary long-acting glucagon-like peptide-2 receptor agonist intended to prevent acute graft versus host disease. Furthermore, it partnered on Larazotide, an 8-amino acid peptide undergoing Phase 2 clinical trials for multi-system inflammatory syndrome. Licensing arrangements were established with Amunix, MHS Care Innovation LLC, Alba Therapeutics Corporation, and EBRIS. Headquartered in Raleigh, North Carolina, 9 Meters Biopharma, Inc. initiated a voluntary petition for liquidation under Chapter 7 of the U.S. Bankruptcy Code on July 17, 2023, in the U.S. Bankruptcy Court for the Eastern District of North Carolina.